Onyx Pharmaceuticals Inc. (ONXX)

ONXX (NASDAQ:Drugs)
$95.65
pos +0.30
+0.31%
Today's Range: 94.39 - 96.49 | ONXX Avg Daily Volume: 1,267,200
Last Update: 05/17/13 - 4:00 PM EDT
Volume: 686,966
YTD Performance: 26.24%
Open: $96.26
Previous Close: $95.35
52 Week Range: $41.26 - $101.57
Oustanding Shares: 72,738,263
Market Cap: 6,935,593,377
6-Month Chart
TheStreet Ratings Grade for ONXX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 13 13
Moderate Buy 0 0 0 0
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.29 1.29 1.27 1.27
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -38.60
Price Earnings Comparisons:
ONXX Sector Avg. S&P 500
-38.60 0.00 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
30.72% 120.54% 279.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue -19.00 0.44 0.13
Net Income -100.00 -12.62 0.00
EPS -100.00 -11.67 0.00
Earnings for ONXX:
EBITDA -0.19B
Revenue 0.36B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $-0.62 $-0.70 $-2.46 $-0.29
Number of Analysts 5 5 5 5
High Estimate $-0.44 $-0.53 $-2.11 $0.87
Low Estimate $-0.86 $-0.87 $-2.93 $-1.76
Prior Year $-0.85 $-0.89 $-3.04 $-2.46
Growth Rate (Year over Year) 26.82% 21.57% 18.95% 88.39%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Volpinacci
Volpinacci: $ONXX continuation triangle in the making = ? Support = S1 ~91 zone http://t.co/Hj0gYCfGfD
2 hours ago from StockTwits Web
1nvestor
1nvestor: The Fab 5 update - 05/18/2013 http://t.co/TlW1ootTa4 $ACT $BA $BDX $HYG $ONXX $APC $HSY $IOC $FISV $ROK $TSLA $ACE $XOM
1 day ago from StockTwits Web
ethan780
ethan780: RT @AndyBiotech: $ONXX mgnt remains bullish on Kyprolis launch, reiterating Q/Q growth & hinting that sales could benefit from increasing duration.(via BAML)
2 days ago from Twitter for Android
AndyBiotech
AndyBiotech: $ONXX mgnt remains bullish on Kyprolis launch, reiterating Q/Q growth & hinting that sales could benefit from increasing duration.(via BAML)
2 days ago from TweetDeck
Consumer_Stocks
Consumer_Stocks: Check out the most widely held #smallcaps $AGNC $PLT $ANN $CYMI $IVC $COO $ODFL $ALGN $ONXX $BRC $RDK http://t.co/usi1f4QuSs
2 days ago from web
ohmsonite
ohmsonite: @MrStemCell don't think my $ONXX $97.5 will be called 2day. OTOH half of my $SRPT will be called @ $36. I have too many $SRPT anyway :)
2 days ago from Twitter for iPhone
micenter
micenter: Onyx Pharmaceuticals $ONXX Showing Bullish Technicals But Could Break Through $101.45 Resistance ( http://t.co/KZGhJK5Yrr )
2 days ago from Marketintelligencecenter.com
Consumer_Stocks
Consumer_Stocks: RT @stockwatchguru: Check out the most widely held #smallcaps $OIS $CBR $NNN $PMI $ONXX $TLEO $INCY $RBC $CNQR $BRC $FTNT http://t.co/D7ldsD3tTm
2 days ago from web
stockwatchguru
stockwatchguru: Check out the most widely held #smallcaps $OIS $CBR $NNN $PMI $ONXX $TLEO $INCY $RBC $CNQR $BRC $FTNT http://t.co/D7ldsD3tTm
2 days ago from web
manufan96
manufan96: $ONXX is a stock i have been in love with since i first started trading with it last year, great company and a great stock
2 days ago from StockTwits Web

Earnings Roundup Real Money Pro($)

By

Doug Kass

| May 08, 2013 | 10:18 AM EDT
Here is my compilation of last night's profit reports.

Even Further Divorced From Logic Real Money Pro($)

By

Timothy Collins

| Apr 11, 2013 | 11:40 AM EDT
The S&P looks set to hit this lofty level, even as it remains unsupported by the economic numbers.

Off the Charts Real Money Pro($)

By

Scott Redler

| Apr 10, 2013 | 6:29 PM EDT
Book profits, don't chase strength.

Consider Playing Catch-Up Via Biotech

By

Jim Cramer

| Apr 10, 2013 | 3:32 PM EDT
Deep-in-the-money call options on these five names could provide a healthy return.

Off the Charts Real Money Pro($)

By

Scott Redler

| Apr 09, 2013 | 5:37 PM EDT
Upward momentum is lagging.

Off the Charts Real Money Pro($)

By

Scott Redler

| Apr 08, 2013 | 6:34 PM EDT
Continue to stay flexible until we get more clarity. 

Ready to Roll With ONYX Real Money Pro($)

By

Timothy Collins

| Mar 28, 2013 | 12:01 PM EDT
Feeling good about the biotechs.
Bullish
Onyx Pharmaceuticals price target increased at JPMorgan
Mar 28, 2013 | 8:42 AM EDT
ONXX price target was increased to $105, said JPMorgan. Palbociclib (palbo, or PD-991), a breast cancer drug, is now included in the va...
Bullish
Onyx Pharmaceuticals price target and estimates increased at Jefferies
Mar 19, 2013 | 8:18 AM EDT
ONXX earnings estimates were increased after a front-line Kyprolis survey showed robust uptake, said Jefferies. Price target is now $10...
Bullish
Onyx Pharmaceuticals numbers increased at Goldman
Mar 15, 2013 | 8:10 AM EDT
ONXX estimates were raised through 2015, Goldman Sachs said. New products can drive growth over the next several quarters. Buy rating a...

Our Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.